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Abstract
Depletion of Wolbachia endosymbionts of human pathogenic filariae using 4–6 weeks of
doxycycline treatment can lead to permanent sterilization and adult filarial death. We investi-
gated the anti-Wolbachia drug candidate ABBV-4083 in the Litomosoides sigmodontis
rodent model to determine Wolbachia depletion kinetics with different regimens. Wolbachia
reduction occurred in mice as early as 3 days after the initiation of ABBV-4083 treatment
and continued throughout a 10-day treatment period. Importantly, Wolbachia levels contin-
ued to decline after a 5-day-treatment from 91.5% to 99.9% during a 3-week washout
period. In jirds, two weeks of ABBV-4083 treatment (100mg/kg once-per-day) caused a
>99.9% Wolbachia depletion in female adult worms, and the kinetics of Wolbachia depletion
were recapitulated in peripheral blood microfilariae. Similar to Wolbachia depletion, in-
hibition of embryogenesis was time-dependent in ABBV-4083-treated jirds, leading to a
complete lack of late embryonic stages (stretched microfilariae) and lack of peripheral
microfilariae in 5/6 ABBV-4083-treated jirds by 14 weeks after treatment. Twice daily treat-
ment in comparison to once daily treatment with ABBV-4083 did not significantly improve
Wolbachia depletion. Moreover, up to 4 nonconsecutive daily treatments within a 14-dose
regimen did not significantly erode Wolbachia depletion. Within the limitations of an animal
model that does not fully recapitulate human filarial disease, our studies suggest that Wolba-
chia depletion should be assessed clinically no earlier than 3–4 weeks after the end of treat-
ment, and that Wolbachia depletion in microfilariae may be a viable surrogate marker for the
depletion within adult worms. Furthermore, strict daily adherence to the dosing regimen with
anti-Wolbachia candidates may not be required, provided that the full regimen is subse-
quently completed.
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Author summary
Onchocerciasis and lymphatic filariasis represent debilitating neglected tropical diseases
that are caused by parasitic filarial nematodes. Current efforts to eliminate onchocerciasis
are hampered by the lack of drugs that lead to permanent sterilization of the adult worms
or provide a macrofilaricidal effect, i.e. kill the adult worms. In the past, doxycycline has
been shown to deplete Wolbachia endosymbionts of filarial nematodes, leading to perma-
nent sterilization and macrofilaricidal efficacy in filariae causing both onchocerciasis and
lymphatic filariasis. However, contraindications and a requirement for at least 4 weeks of
doxycycline treatment impair its broader use, creating a need for drugs with a shorter
treatment regimen and potentially fewer contraindications. ABBV-4083 is such an anti-
Wolbachia candidate that was efficacious in several filarial animal models and has recently
been tested in a phase 1 clinical trial. The present studies addressed several points that are
important for subsequent phase 2 clinical trials, namely the comparison of once vs. twice-
per-day treatments, the impact of missed treatments, and a comparison of the kinetics of
Wolbachia depletion in adult worms and microfilariae, the latter of which has the poten-
tial to be a surrogate indicator to avoid the necessity of surgically removing nodules with
adult worms at repeated time points.
Introduction
Onchocerciasis and lymphatic filariasis are neglected tropical diseases that are caused by the
filarial nematodes Onchocerca volvulus and Wuchereria bancrofti, Brugia malayi and Brugia
timori, respectively [1]. During onchocerciasis vision loss and severe dermatitis can occur,
whereas one third of lymphatic filariasis patients develop lymphedema and hydrocele [2, 3].
Due to the severity of these debilitating diseases that present a huge socioeconomic problem in
endemic countries, the World Health Organization (WHO) has targeted both diseases for
elimination [2, 3]. Therefore, mass drug administrations have been performed over the last
decades with ivermectin for onchocerciasis in sub-Saharan Africa, ivermectin plus albendazole
for lymphatic filariasis in sub-Saharan Africa, and diethylcarbamazine (DEC) plus albendazole
for lymphatic filariasis outside of Africa [2, 3]. However, these regimens are mainly microfilar-
icidal, leading to the loss of the filarial offspring, the microfilariae. They also temporarily
inhibit the embryogenesis of the female adult worms, but do not kill the adult worms, i.e. pro-
duce a macrofilaricidal effect. Therefore, these treatments need to be given on an annual or
biannual basis to reduce transmission of the filariae for the reproductive life-span of the female
adult worms, which can be as long as 15 years for onchocerciasis. Recently, moxidectin, which
demonstrates a prolonged clearance of microfilariae in comparison to ivermectin, was regis-
tered as a new drug for onchocerciasis, providing the potential to more effectively reduce
transmission between treatment rounds and accelerate elimination of onchocerciasis [4]. Fur-
thermore, administration of a triple therapy consisting of ivermectin, DEC and albendazole
was introduced for lymphatic filariasis, and it is now recommended by the WHO in areas
non-endemic for onchocerciasis [5], as it leads to a prolonged depletion of the microfilariae
and may also provide macrofilaricidal efficacy [6, 7]. However, potential drug-induced serious
adverse events in areas co-endemic for the filarial nematode Loa loa in the case of moxidectin
as well as L. loa and O. volvulus [8] in the case of the triple therapy, may hamper the implemen-
tation of those treatments in those areas. Furthermore, with lower endemicities of onchocerci-
asis and lymphatic filariasis, the cost effectiveness of community-based MDA programs is
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reduced [9], and modelling studies suggest that the reduction of required treatment rounds by
triple therapy will be less significant in areas of lower endemicity [10]. Therefore, new macrofi-
laricidal drugs are needed for case management and for clearance of residual foci in order to
eliminate onchocerciasis and lymphatic filariasis.
Such macrofilaricidal efficacy can be achieved by drugs that target Wolbachia endosymbi-
onts, which are present in most human pathogenic filariae, including those causing lymphatic
filariasis and onchocerciasis, but, notably, not in L. loa. Treatment of either onchocerciasis or
lymphatic filariasis patients with doxycycline for 4–6 weeks has been shown to deplete Wolba-
chia bacteria, leading to permanent sterilization of the female worms and providing a slow and
therefore safe macrofilaricidal effect [11–16]. However, the need for prolonged treatment (at
least 4 weeks) and contraindications in children under age 8 and in pregnant and lactating
women prevent the broader use of doxycycline for filarial diseases.
ABBV-4083 is a tylosin analogue which has improved potency and oral bioavailability com-
pared to tylosin and has been shown to be efficacious in rodent models using the filarial nema-
todes Litomosoides sigmodontis, B. malayi and Onchocerca ochengi [17, 18]. Thus, ABBV-4083
represents a promising anti-Wolbachia candidate, and its safety in humans has recently been
assessed in a phase 1 clinical trial (https://www.dndi.org/diseases-projects/portfolio/abbv-
4083/).
In the current studies we addressed several points that are important for informing the
design of phase 2 clinical trials of anti-Wolbachia candidates. These involved i) the determina-
tion of the kinetics of Wolbachia depletion in adult worms during and after treatment; ii) the
investigation of alternate dosing regimens, i.e. the comparison of a once (QD) and twice daily
(BID) treatment; iii) the assessment of whether Wolbachia depletion in microfilariae can be
used as surrogate marker for the depletion in adult worms; and iv) the impact of a later catch-
up of missed treatment days. For these experiments we used the L. sigmodontis rodent model
[19, 20], as L. sigmodontis harbors Wolbachia endosymbionts and was previously used for pre-
clinical studies of direct-acting and Wolbachia-targeting drug candidates, with good predictiv-
ity of the parasitological outcomes of later doxycycline clinical trials [21–27].
In the L. sigmodontis model, infective L3 larvae are transmitted during the blood meal of
the tropical rat mite Ornithonyssus bacoti. The larvae migrate to the thoracic cavity, where they
molt into adult worms within 30 days after infection (dpi) [28]. Starting ~8 weeks after infec-
tion, female worms release microfilariae, which circulate in the peripheral blood. Experiments
were performed in L. sigmodontis-infected mice with treatment start after the molt into adult
worms (35/36dpi) and in L. sigmodontis-infected jirds after the development of microfilaremia
(3–4 months after infection). Two different rodent hosts were chosen, as only 50% of BALB/c
mice develop microfilaremia, which is comparable to human lymphatic filariasis [29], and
BALB/c mice clear the infection around 100 days post infection [20]. In contrast, the suscepti-
bility of jirds to infections with L. sigmodontis is increased, leading to the development of
microfilaremia in the majority of animals and infections that last for more than one year [20].
Thus, jirds were used in our long-term experiments investigating microfilariae and embryo-
genesis, whereas mice were initially used to test the drug-efficacy against the female adult
worms.
Our studies reveal that Wolbachia reduction occurs as soon as 3 days after treatment onset
and continues during the weeks following the end of treatment. Wolbachia depletion by
ABBV-4083 was not significantly improved by BID treatment in comparison to QD treatment.
The kinetics of Wolbachia depletion in microfilariae coincide with the Wolbachia depletion in
female adult worms, indicating its value as potential early clinical marker of efficacy. Finally,
missed treatments could be given at later time points without impairing the Wolbachia deple-
tion and parasitological outcome.
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Materials and methods
Ethics statement
All animal experiments were performed in accordance with the European Union Directive
2010/63/EU and were approved by the Landesamt fu¨r Natur, Umwelt und Verbraucherschutz,
Cologne, Germany (AZ 84–02.04.2015.A507). Animal welfare was scored on a scale from A-C
for symptoms considering appearance, injuries, weight loss, and behavior. A score of A
required daily observations of the symptoms, a score of B, consultation of the project leader or
a veterinarian, and a score of C the immediate euthanization of the affected animal. For eutha-
nization, animals were exposed to an overdose of isoflurane.
Test agents
Compound ABBV-4083, Lot 2263872–0, was used for testing and provided by AbbVie. Doxy-
cycline (Sigma Aldrich, St. Louis, MO, USA) was used as control and was stored at 4˚C and
suspended shortly before application in distilled water. ABBV-4083 was also stored at 4˚C and
homogenized in 0.5% hydroxypropylmethylcellulose/0.02% Tween 80 (Sigma Aldrich) at 4˚C
overnight on a magnetic stirrer. This preparation was aliquoted, stored at -20˚C and used for
up to 5 subsequent treatment days.
Animals
Female jirds (Meriones unguiculatus) and female BALB/c J mice were obtained from Janvier
(Saint-Berthevin, France) and were housed in individually ventilated cages at the animal facil-
ity of the Institute of Medical Microbiology, Immunology and Parasitology, University Hospi-
tal Bonn, with free access to food and water. The animals were maintained on a 12h day/night
cycle at 20–26˚C and a humidity of 30–70%. For enrichment, animals were provided wooden
sticks and nestlets.
Study design of mice infected with L. sigmodontis
Female BALB/c mice (8–10 weeks old) were naturally infected by exposure to mites (O. bacoti)
containing L. sigmodontis L3 larvae. The same batch of mite-containing bedding was used to
infect all animals of one study design at one time point as previously described [30]. Treatment
started 35 or 36dpi for all study designs in mice and all treatments were given by oral gavage at
the indicated doses either QD or BID.
In total, three mouse studies were performed:
Mouse study I: Four experimental groups were included in this study. Two groups received
75mg/kg QD ABBV-4083 (n = 6/group) for 3 or 7 days, whereas two additional groups were
treated QD for 3 or 7 days with an equal volume of vehicle (n = 6). In this experiment blood
was obtained 1 and 7 hours after the first and last morning gavage and pipetted onto DBS filter
cards (Whatman 903 Protein saver card, Sigma-Aldrich, Germany) for pharmacokinetic analy-
ses. Vehicle and ABBV-4083 groups were euthanized 38 and 42dpi.
Mouse study II: Ten experimental groups were included in this study. Two groups received
75mg/kg QD ABBV-4083 (n = 6/group) for 5 days, two groups received 75mg/kg QD ABBV-
4083 (n = 6/group) for 10 days and two groups 75mg/kg BID ABBV-4083 (150mg/kg/day;
n = 6/group) for 5 days. Doxycycline (n = 6) was administered at the human bioequivalent
dose of 40mg/kg BID for a suboptimal duration of 10 consecutive days. Three groups of con-
trol mice were treated once daily for 5 and 10 days with an equal volume of vehicle (n = 6).
Blood was obtained by puncture of the facial vein 1 and 7 hours after the last morning gavage
and pipetted onto DBS filter cards for pharmacokinetic analyses. Necropsy and further
Wolbachia depletion kinetics
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007636 August 5, 2019 4 / 19
analyses were performed one day after treatment end at 40, 45, and 63dpi (5, 10 and 28 days
after treatment start). Vehicle-treated mice were euthanized 40, 45, and 63dpi, doxycycline
controls at 63dpi.
Mouse study III: Five experimental groups were included in this study. Three groups received
43, 50, or 75mg/kg QD ABBV-4083 (n = 5/group) for 5 days, whereas one group was treated for 5
days with 43mg/kg BID ABBV-4083 (n = 5/group). Controls received an equal volume of vehicle
twice a day for 5 days (n = 5). In this experiment blood was obtained 2, 8 and 24 hours after the
first morning gavage (before the 8h and 24h treatment) and pipetted onto DBS filter cards for
pharmacokinetic analyses. Vehicle and ABBV-4083 groups were euthanized 41dpi.
Study design of jirds infected with L. sigmodontis
Female jirds (8–9 weeks old) were naturally infected with L. sigmodontis L3 larvae by exposure
to infected O. bacoti mites, using the same batch of mite-containing bedding to infect all ani-
mals of one study. At 11 weeks after infection (wpi), infected jirds were checked for peripheral
microfilarial counts and microfilaremic animals were allocated to the different treatment
groups. Treatment of jirds was initiated 12-15wpi and all treatments were given by oral gavage.
Jird study I: Six experimental groups were tested in this study. Group 1 received 100mg/kg
QD ABBV-4083 for 7 consecutive days (n = 6), and groups 2–4 received 100mg/kg QD ABBV-
4083 for 14 consecutive days (n = 6 per group). Group 5 received 40mg/kg BID doxycycline
for a suboptimal duration of 14 consecutive days (n = 6). Group 6 received an equal volume of
ABBV-4083 vehicle and was used as control (n = 6). Necropsy of group 1 was performed 1
week after treatment start (wpt), group 2 at 2wpt, group 3 at 4wpt and groups 4–6 at 14wpt.
Jird study II: Seven experimental groups were tested in this study. Groups 1–6 received
ABBV-4083 at 25mg/kg QD for 7, 10 or 14 consecutive days (n = 6–7 per group), 7 days with
missed treatments on day 6 and 8 (n = 6), or 14 days with missed treatments on day 6, 8, 13
and 15 (n = 6). Missed treatments were given the following days so that the animals received 7
or 14 treatments in total over a period of 9 or 18 days, respectively. Controls received an equal
amount of vehicle once per day for 14 days (n = 6) and as a positive control jirds were treated
for 14 days with 50mg/kg QD ABBV-4083 (n = 6). Necropsies were performed at 8wpt.
Assessment of adult worm and microfilariae counts
At necropsy infection of mice and jirds was confirmed by flushing the pleural cavity with 1ml
PBS and by screening for adult worms in the thoracic cavity as well as the peritoneum. Isolated
worms were separated, sex determined, counted and individually frozen for subsequent Wol-
bachia analysis or stored in 70% ethanol for analysis of embryogenesis.
For jird experiments, peripheral blood microfilariae levels were quantified at 1- to 2-week
intervals by microscopy starting at 11wpi until the day of necropsy. For blood collection, the
vena saphena was punctured and 10μL of peripheral blood were directly transferred into 190μl
of red blood cell lysis buffer (BioLegend, San Diego, CA, USA) and stored at 4˚C until analysis.
After resuspension, 10μl of the suspension were transferred to a microscopic slide and microfi-
lariae were counted from the complete slide using a microscope. If less than 10 microfilariae
were counted, the tubes were centrifuged at 400g for 5 minutes, the supernatant was discarded,
and the pellet resuspended and completely transferred to a microscope slide for counting.
Quantification of Wolbachia
Depletion of endosymbiotic Wolbachia was determined by qPCR using primers for Wolbachia
single copy gene ftsZ (GenBank Accession No.: AJ010271) and normalized to the L. sigmodon-
tis actin gene (act) (GenBank Accession No.: GU971367) as previously described [27]. If
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present, 10 female worms per animal were frozen at -20˚C for later analysis of the Wolbachia
ftsZ/act ratio by duplex real-time PCR using Qiagen’s QuantiNova on a Rotorgene Q 5-Plex
(Qiagen, Hilden, Germany). The PCR was performed in triplicate. The following primer pairs
(MicroSynth; Switzerland) and TaqMan probes (biomers; Germany) were used: LsFtsZ FW
cgatgagattatggaacatataa, LsFtsZ RV ttgcaattactggtgctgc, LsFtsZ TQP 5’6-FAM cagggatgggtgg
tggtactggaa 3’TAMRA, LsActin FW atccaagctgtcctgtctct, LsActin RV tgagaattgatttgagctaatg,
LsActin TQP 5’HEX actaccggtattgtgctcgatt 3’TAMRA. The qPCR consisted of 45 cycles with a
melting temperature of 95˚C for 5 sec and an annealing temperature of 58˚C for 30 sec. The
standard curve used was a mix of LsFtsZ and LsActin plasmids.
For Wolbachia quantification from microfilariae, 50μL of peripheral blood were lysed with
950μL RBC lysis buffer (Biolegend) at room temperature for at least 5 minutes. After centrifu-
gation at 400g, the supernatant was discarded, and the pellet resuspended in 200μl AE buffer
(Qiagen). A known number of peripheral blood microfilariae (if present 10–30 microfilariae)
were stored in AE-buffer at 4˚C until analysis. The PCR was performed as described for the
adult worms. As microfilariae are less variable in size as adult worms, ftsZ values per microfi-
laria are shown.
Statistics
ABBV-4083 efficacy was determined based on the reduction of Wolbachia ftsZ/act from female
adult worms (primary efficacy parameter). Secondary efficacy parameters included in jird
experiments the reduction of Wolbachia ftsZ gene from microfilariae, the inhibition of
embryogenesis and the clearance of microfilariae. Statistical analyses were performed using
GraphPad Prism software Version 8.02 (GraphPad Software, San Diego, USA). Distribution of
data was tested for normality by d‘Agostino & Pearson test. Differences between multiple
groups that were not normally distributed were tested for statistical significance using Krus-
kal-Wallis followed by Dunn’s multiple comparison test. Normally distributed data of multiple
groups were tested for statistical significance using 1-way-ANOVA followed by Sidak’s multi-
ple comparison test. p values� 0.05 were considered statistically significant.
Results
Kinetics of Wolbachia decline in L. sigmodontis during and after ABBV-
4083 treatment
To assess the kinetics of Wolbachia depletion in L. sigmodontis adult filariae during and subse-
quent to ABBV-4083 treatment, we conducted three studies in L. sigmodontis-infected mice.
In the first, animals were treated at 35dpi with either a high dose (75mg/kg QD) of ABBV-
4083 previously shown to be effective or vehicle QD for 3 or 7 days (Fig 1A). Necropsies were
performed in the ABBV-4083 or vehicle treated animals one day after the last treatment (38,
42dpi, respectively). ABBV-4083 concentrations in blood obtained at two separate time points
after oral dosing in mice were comparable to those obtained in satellite pharmacokinetic stud-
ies at the same dose [18]. In the second study, two additional dosing durations were examined
to more completely assess the acute kinetics of Wolbachia depletion. In addition, the impact of
a washout period after the end of treatment was assessed. Mice received 75mg/kg ABBV-4083
for 5 days QD (1x 75mg/kg per day) with necropsies either one day after the last treatment
(40dpi) or a washout period of ~3 weeks (63dpi; Fig 1A). Additional groups received ABBV-
4083 QD for 10 days and were analyzed at 45dpi (no washout) and 63dpi (washout). Separate
vehicle controls for each necropsy day and doxycycline controls (40mg/kg BID 10 days) with
necropsy at 63dpi were included.
Wolbachia depletion kinetics
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ABBV-4083 treatment reduced endosymbiotic Wolbachia in a treatment duration depen-
dent manner that correlated across both studies. After treatment end, 3, 5, 7 or 10 days of QD
treatment reduced the Wolbachia ftsZ/act ratio compared to the respective vehicle control by
84.9%, 91.5%, 94.0% and 98.7%, respectively (Fig 1B). Wolbachia levels continued to decline
during the washout period, and at 63dpi, the 5- and 10-day QD treatment regimens reduced
the Wolbachia ftsZ/act ratio compared to the respective vehicle control by 99.94% and 99.98%,
respectively. All differences in Wolbachia burden by ABBV-4083 treatment compared to the
respective vehicle controls were statistically significant (p<0.01 after 3d treatment; p<0.001
after 5, 7, 10d treatment). Taken together, these results indicate that the Wolbachia levels
decline in an approximately log-linear fashion between 3 and 10 days of treatment with
ABBV-4083 and continue during the weeks following the end of treatment. As observed previ-
ously [18], control animals receiving a suboptimal 10-day doxycycline treatment exhibited a
significantly smaller reduction in Wolbachia ftsZ/act ratio (93.3%, p<0.001) compared to ani-
mals treated with ABBV-4083 for the same duration (10 days).
Effects of QD vs. BID dosing of ABBV-4083 on Wolbachia decline in L.
sigmodontis infected mice
Two additional arms in the second study above allowed the comparison of 5 days of BID dos-
ing of ABBV-4083 to either 5 or 10 days of QD dosing, with necropsies either one day after the
last treatment or after a washout period (Fig 1A). At treatment end, 75mg/kg ABBV-4083
twice daily for 5 days produced a decline in Wolbachia only marginally better (94.8% com-
pared to the respective vehicle control) than the same dose once daily for 5 days (91.5%,
p>0.99), and inferior to the same total dose given over 10 days once daily (98.7%, p<0.05, Fig
1B). Because of the high (>99.9%) responses at this dose, no statistically significant differences
between ABBV-4083 dosing regimens were observed after the washout period.
A third study in mice also compared QD and BID regimens, but at lower doses. Mice
received 5 days of ABBV-4083 treatment with one of four regimens (43mg/kg QD, 43mg/kg
BID, 50mg/kg QD or 75mg/kg QD) at 36dpi and were necropsied at day 41dpi (Fig 1C). Vehi-
cle controls received 5 days of BID treatments. Five days of ABBV-4083 treatment reduced the
ftsZ/act ratio in female worms in a dose dependent manner analyzed one day after treatment
end at 41dpi (Fig 1D). ABBV-4083 treatment at 43mg/kg QD reduced the Wolbachia ftsZ/act
ratio in female adult worms by 64.2%, at 43mg/kg BID by 79.2%, at 50mg/kg QD at 77.6% and
at 75mg/kg QD at 94.5% compared to vehicle treated controls. All differences in Wolbachia
burden were statistically significant in comparison to vehicle controls (p<0.001).
The above results indicate that in L. sigmodontis-infected mice, five days of once daily dos-
ing of ABBV-4083 at 75mg/kg are sufficient to reduce Wolbachia levels by>90% and that
Fig 1. Wolbachia decline during and after ABBV-4083 treatment with twice daily treatment showing no significant superiority over once daily
treatment. A, experimental design. 8-week-old female mice (n = 5–8 mice/group) were infected naturally with L. sigmodontis. At 35dpi the animals
were treated orally either with ABBV-4083 (1x (QD) or 2x (BID) 75mg/kg (mpk) per day) for 3, 5, 7 or 10 days with necropsies at 38, 40, 42, 45 & 63dpi
or doxycycline (DOX, 2x 40mg/kg per day) for 10 days and necropsy at 63dpi. Controls received an equal amount of vehicle (VEH, necropsy 38, 40, 42,
45 or 63dpi). B, Wolbachia ftsZ/act per female adult worm was quantified by real-time PCR (38dpi: VEH 3d = 60 worms; ABBV-4083 QD 3d = 36
worms; 40dpi: VEH 3d = 57 worms; ABBV-4083 QD 5d = 52 worms; ABBV-4083 BID 5d = 59 worms; 42dpi: VEH 7d = 59 worms; ABBV-4083 QD
7d = 52 worms; 45dpi: VEH 10d = 51 worms; ABBV-4083 QD 10d = 41 worms; 63dpi: VEH 5d = 43 worms; ABBV-4083 QD 5d = 37 worms; ABBV-
4083 BID 5d = 60 worms; ABBV-4083 QD 10d = 47 worms, DOX BID 10d = 48 worms). C, experimental design. 8- to 10-week-old female mice (n = 5
mice/group) were infected naturally with L. sigmodontis and treated orally with ABBV-4083 (1x 43mg/kg; 2x 43mg/kg; 1x 50mg/kg; 1x 75mg/kg per
day) or VEH for 5 days starting 36dpi with necropsies at 41dpi. D, Wolbachia ftsZ/act per female worm (VEH 5d = 37 worms; ABBV-4083 43mg/kg
QD 5d = 27 worms; ABBV-4083 43mg/kg BID 5d = 19 worms; ABBV-4083 50mg/kg QD 5d = 26 worms; ABBV-4083 75mg/kg QD 5d = 17 worms).
Data were tested for normal distribution by d‘Agostino & Pearson test. Statistical significance of not normally distributed data (B, D) was analyzed by
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depletion continues to>99% after a washout period. At both this and a lower dose, BID treat-
ment led to a small, non-significant improvement in Wolbachia depletion in comparison to
QD treatment regimens for the same duration.
Wolbachia depletion in microfilariae coincides with the depletion in female
adult worms
While the adult worm burden starts to naturally decline in L. sigmodontis infected BALB/c
mice ~70dpi, ~3 weeks after the development of microfilaremia [20], jirds are more permissive
to long-term infections with L. sigmodontis, allowing an analysis for >5 months during patent
(microfilariae-positive) infections [20]. We therefore assessed the effects of ABBV-4083 treat-
ment on the Wolbachia depletion kinetics in female adult worms in jirds and compared it to
the depletion observed in microfilariae, to ascertain the potential of Wolbachia depletion in
microfilariae as a clinical surrogate indicator. Microfilariae positive jirds were treated QD with
100mg/kg ABBV-4083 for 7 or 14 days with necropsies at 1, 2, 4 and 14wpt. Controls received
an equal volume of vehicle for 14 days QD or a suboptimal treatment with doxycycline (40mg/
kg BID, 14 days) and were analyzed at 14wpt (Fig 2A).
Treatment with ABBV-4083 reduced the Wolbachia levels in female adult worms in a time-
dependent manner (Fig 2B). At 1, 2 and 4wpt, 92.5%, 97.0% and 99.7% of Wolbachia were
depleted, respectively, in comparison to the vehicle controls. After an extended washout
(14wpt) the Wolbachia levels remained 99.9% depleted. Suboptimal two weeks of doxycycline
treatment were not sufficient for long-term clearance of the Wolbachia: a 132% increase was
observed in this group compared to the vehicle controls at 14wpt.
In accordance with the Wolbachia depletion in female adult worms, Wolbachia ftsZ levels
in microfilariae of the ABBV-4083 and doxycycline treated groups were reduced by 1wpt by
97.5 and 97.8%, respectively, with only one out of six animals in both groups having detectable
Wolbachia in microfilariae (Fig 2C). At 5wpt microfilariae from all 14-day ABBV-4083 and
14-day doxycycline treated animals had no detectable Wolbachia ftsZ. Whereas ABBV-4083
treated animals continued to have no detectable Wolbachia ftsZ levels until the end of the anal-
ysis at 13wpt, 1 out of 6 doxycycline treated animals had detectable Wolbachia ftsZ levels in
microfilariae at 9wpt again and by 11 and 13wpt all microfilariae of doxycycline treated ani-
mals had detectable Wolbachia ftsZ levels (mean Wolbachia ftsZ reduction of 96.1%, 25.4%
and 20.4% at 9, 11 and 13wpt), reaching levels equivalent to the start of the study.
These data indicate that Wolbachia depletion in microfilariae temporally correlates with the
depletion in female adult worms (p = 0.02; r2 = 0.432 at 13/14wpt; Fig 2D), presenting a poten-
tial surrogate marker for the efficacy of Wolbachia-targeting compounds.
Kinetics of ABBV-4083-induced clearance of microfilaremia and inhibition
of filarial embryogenesis
In addition to the depletion kinetics of Wolbachia in adult worms and microfilariae, the
impact of ABBV-4083 treatment on the clearance of peripheral microfilariae along with the
inhibition of the embryogenesis of female adult worms over time was assessed.
Before treatment start all jirds included in this study were microfilariae positive. At 11wpt
the first animal treated for 14 days with ABBV-4083 (QD 100mg/kg) cleared all microfilariae
from the peripheral blood. By 14wpt 5 out of 6 ABBV-4083 treated jirds were amicrofilaremic
and the one remaining microfilariae positive jird had declined from 809 at baseline to 1 micro-
filaria / 10μl blood (Fig 3A). Consistent with previous findings [18], all suboptimal doxycycline
treated animals were microfilariae positive at 14wpt.
Wolbachia depletion kinetics
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Fig 2. Wolbachia depletion in microfilariae coincides with the depletion in female adult worms. A, experimental design. Female jirds were infected naturally with
L. sigmodontis and at 12wpi treated orally with ABBV-4083 (1x (QD) 100mg/kg (mpk) per day, 7 or 14 days, n = 6) or doxycycline (DOX, 2x (BID) 40mg/kg per day,
14 days, n = 6). Vehicle treated animals served as controls (VEH, n = 6). B, Wolbachia ftsZ/act ratio of isolated female adult worms after necropsy at 1, 2, 4, and 14
weeks after treatment (VEH = 30 worms; DOX = 53 worms; ABBV-4083 1wpt = 54 worms; ABBV-4083 2wpt = 30 worms; ABBV-4083 4wpt = 51 worms; ABBV-4083
14wpt = 58 worms). Data were tested for normal distribution by d‘Agostino & Pearson test. Statistical significance of not normally distributed data in B was analyzed
by Kruskal-Wallis followed by Dunn’s multiple comparison test. The line indicates the median. ���p<0.001, compared with VEH. C, Wolbachia ftsZ/microfilaria over
time (Mean + SEM) and percentage reduction compared with VEH for doxycycline (blue) and ABBV-4083 (green) 14-day treated groups. D, Spearman correlation of
Wolbachia ftsZ/microfilariae and median ftsZ/female adult worms from the same animals at 14wpt.
https://doi.org/10.1371/journal.pntd.0007636.g002
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In accordance with the peripheral blood microfilariae counts over time, no marked reduc-
tion of the embryogenesis was observed one week after treatment onset with ABBV-4083 (QD
100mg/kg), with similar ratios of eggs, morulae, pretzel and stretched microfilariae stages in
the uteri of the analyzed worms as in the vehicle control (Fig 3B). Four weeks after treatment
onset with ABBV-4083, a significant reduction in eggs (p<0.01), pretzel (p<0.05) and
stretched microfilariae (p<0.01) stages occurred in comparison to the vehicle controls and at
14wpt, a complete lack of stretched microfilariae stages in the ABBV-4083 treated group was
observed along with statistically significantly reduced early embryonal stages (eggs & pretzel:
p<0.001, morulae p<0.01). In comparison, suboptimal 2 weeks of doxycycline treatment
reduced the number of early embryonal stages (egg p<0.001 and morulae p<0.05) by 14wpt,
whereas two female worms harbored stretched microfilariae at that time point. In summary,
ABBV-4083 treatment in jirds cleared microfilariae from the peripheral blood, completely
inhibited embryogenesis and reduced all embryonal stages by 14wpt.
Sequential daily treatment with ABBV-4083 is not essential for depletion of
Wolbachia and microfilariae in the L. sigmodontis rodent model
Since strict adherence to multi-day drug administration can present a challenge to successful
therapy, we assessed the impact of missed treatments on the efficacy of ABBV-4083 in a preclin-
ical model. In this study three groups of jirds received 25mg/kg ABBV-4083 QD for 7, 10 or 14
consecutive days, respectively. Two other groups received discontinuous 7 and 14 treatments,
skipping on days 6 and 8, and days 6, 8, 13 and 15, respectively, with once daily administration
subsequently continuing to complete the regimen (Fig 4A). A lower, suboptimal dose of 25mg/
kg ABBV-4083 was used in order to allow the identification of less prominent changes in the
efficacy of continuous and discontinuous treatments. Positive controls received ABBV-4083
QD at 50mg/kg for 14 consecutive days and vehicle treated animals served as negative control.
Fig 3. ABBV-4083 treatment clears microfilaremia and inhibits filarial embryogenesis. A, Microfilariae counts over time in L. sigmodontis infected jirds that were
treated for 14 days with ABBV-4083 (1x 100mg/kg per day, n = 6), doxycycline (DOX, 2x 40mg/kg per day, 14 days, n = 6) or (1x VEH per day, n = 6) starting at 12
wpi. Data are presented as mean + SEM. B, embryograms from female adult worms isolated from L. sigmodontis infected jirds treated orally either with ABBV-4083
(1x 100mg/kg per day, 7 or 14 days, n = 6 jirds), doxycycline (DOX, 2x 40mg/kg per day, 14 days, n = 6 jirds) or vehicle (VEH, n = 6 jirds) at the time of necropsy 1, 4,
14 wpt (VEH = 10 worms; DOX = 20 worms; ABBV-4083 1wpt = 25 worms; ABBV-4083 4wpt = 20 worms; ABBV-4083 14wpt = 25 worms). The following embryonic
stages were counted: egg, morula, pretzel and stretched microfilariae (MF). Data are presented as median.
https://doi.org/10.1371/journal.pntd.0007636.g003
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Eight weeks after treatment start, jirds treated with ABBV-4083 QD at 50mg/kg for 14 days
had a Wolbachia reduction of 99.8% in comparison to vehicle controls (Fig 4B). Lower doses
of ABBV-4083 QD at 25mg/kg depleted the Wolbachia ftsZ/act ratio in a treatment duration
dependent manner by 47.3%, 67.9% and 98.4% after 7, 10 and 14 consecutive days of treat-
ment, respectively. Discontinuous daily treatment with 7 or 14 doses did not impair the Wol-
bachia depletions compared to continuous treatment, resulting in a reduction by 70.8% and
99.1%, respectively (Fig 4B). Wolbachia depletion in microfilariae at 8wpt (Fig 4C) correlated
with the Wolbachia depletion in the adult worms (p<0.0001; r2 = 0.377, Fig 4D), reaching a
mean Wolbachia reduction in microfilariae of jirds treated with ABBV-4083 QD at 50mg/kg
for 14 days of 100% and at QD doses of 25mg/kg for 7, 10 and 14 consecutive days of 29.9% (6/
6 animals with detectable Wolbachia in microfilariae), 90.6% (2/6 animals with detectable Wol-
bachia in microfilariae) and 90.2% (1/7 animals with detectable Wolbachia in microfilariae),
respectively. Non-consecutive treatments for 7 and 14 days resulted in a Wolbachia reduction
in microfilariae of 88.9% (4/5 animals with detectable Wolbachia in microfilariae) and 96.9%
(1/6 animals with detectable Wolbachia in microfilariae), respectively.
Although this study was not designed to continue long enough to fully ascertain the effect
on peripheral microfilaremia, microfilariae levels started to decline at 8 weeks after treatment
start (Fig 4E), reaching statistical significance in animals treated for 14 days with 50mg/kg
ABBV-4083 (p<0.01) and 25mg/kg ABBV-4083 on 14 non-consecutive days (p<0.05). Con-
sistent with this trend and with the Wolbachia reduction shown in Fig 4B, later embryonal
stages (pretzel and stretched microfilariae) were absent in the majority of female adult worms
isolated from animals that received 14 days of treatment (Fig 4F). Reductions in later embryo-
nal stages were independent of continuous or discontinuous ABBV-4083 treatment (Fig 4F;
absence of pretzel stages: 14-day continuous group 68.7% (11/16 worms), 14-day discontinu-
ous group 100% (8/8 worms), 50mg/kg group 100% (6/6 worms); absence of stretched microfi-
lariae stages: 14-day continuous group absent in 93.7% (15/16 worms), 14-day discontinuous
group 87.5% (7/8 worms), 50mg/kg group 100% (6/6 worms)). The population of the early
embryonic morula stage was also reduced in the groups treated for 14 days (median reduction
of 82% in 50mg/kg group; 87% in continuous group, 89% in discontinuous group) compared
to vehicle or 7-day treated animals (median reduction in comparison to vehicle controls of
11% in continuous group and -13% in discontinuous group).
Discussion
The present studies addressed several important aspects of the in vivo efficacy of the novel
anti-Wolbachia agent ABBV-4083 [17, 18]. Using highly suppressive doses, the kinetics of
Wolbachia depletion in female adult worms were investigated and the potential of using
Fig 4. Continuous daily treatments with ABBV-4083 are not required for depletion of Wolbachia and microfilariae. A, experimental design.
L. sigmodontis-infected jirds were treated orally either with ABBV-4083 1x 25mg/kg (mpk) QD consecutively for 7, 10 or 14 days (n = 6–7,
consecutively (Con) treated group), or discontinuously (Dis) for 7 days total with skipped treatments on days 6 and 8 or discontinuously for 14
days with skipped treatments on days 6, 8, 13, and 15 (n = 6). Vehicle treated animals served as negative controls (VEH, n = 7), ABBV-4083 1x
50mg/kg for 14 day treated animals served as positive control. B, Wolbachia ftsZ/act ratio of isolated female adult worms at 8 weeks after treatment
start (VEH = 12 worms; ABBV-4083 50mg/kg Con = 16 worms; ABBV-4083 25mg/kg 7d Con = 23 worms; ABBV-4083 25mg/kg 7d Dis = 9
worms; ABBV-4083 25mg/kg 10d Con = 19 worms; ABBV-4083 25mg/kg 14d Con = 27 worms; ABBV-4083 25mg/kg 14d Dis = 13 worms). Data
were tested for normality by d‘Agostino & Pearson test. Statistical significance of not normally distributed data shown in B was analyzed by
Kruskal-Wallis followed by Dunn’s multiple comparison test. ���p<0.001. C, Wolbachia ftsZ/microfilaria over time (mean + SEM). D, Spearman
correlation of Wolbachia ftsZ/microfilariae and median ftsZ/female adult worms from the same animals at 8 wpt. E, Microfilariae counts over time
(mean + SEM) and F, embryograms from female adult worms (VEH = 6 worms; ABBV-4083 50mg/kg Con = 6 worms; ABBV-4083 25mg/kg 7d
Con = 10 worms; ABBV-4083 25mg/kg 7d Dis = 1 worm; ABBV-4083 25mg/kg 10d Con = 7 worms; ABBV-4083 25mg/kg 14d Con = 16 worms;
ABBV-4083 25mg/kg 14d Dis = 8 worms). The following embryonic stages were counted: egg, morula, pretzel and stretched MF, as well as
degenerated early (egg, morula) and late (pretzel, stretched MF) stages. Data are presented as median.
https://doi.org/10.1371/journal.pntd.0007636.g004
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Wolbachia depletion in microfilariae as surrogate marker was ascertained. Using lower doses,
the pharmacological aspects of more or less frequent dosing were analyzed, including compari-
sons of BID and QD treatment as well as the effect of nonsequential daily dosing as a model of
incomplete adherence. These results provide useful guidance for the design of future clinical
efficacy studies with ABBV-4083 and subsequent anti-Wolbachia candidates for the treatment
of filariasis. One limitation of these studies is the use of an animal model employing a surro-
gate filarial nematode to model human filarial infections. Factors like the increased life expec-
tancy of the human filarial nematodes, differences in Wolbachia densities and differences in
the pharmacokinetics of ABBV-4083 in rodents and humans, as well as accessibility of the
drug to the filariae (adult L. sigmodontis worms in the thoracic cavity vs. adult O. volvulus
worms in subcutaneous nodules) may impact the translation of our results to human filarial
infections. Furthermore, treatments in mice were performed before the occurrence of nema-
tode patency, which will not be the case for clinical trials in filariasis patients. Nevertheless,
our studies provide important information for designing aspects of a clinical program for
ABBV-4083, including the rational selection of dosing regimens and the timing for investiga-
tion of Wolbachia depletion in microfilariae as a surrogate marker to ascertain both drug activ-
ity and possible bacterial recrudescence. Furthermore, although the filarial nematode utilized
in our studies differs from the human pathogens, the target of drug activity (Wolbachia) is
highly similar, giving relevance to the pharmacological aspects of ABBV-4083 investigated
here. In addition, 200mg doxycycline for 4 weeks were previously shown to have significant
macrofilaricidal efficacy in both lymphatic filariasis as well as onchocerciasis [1, 31, 32], indi-
cating that drug exposures may be sufficient in the two anatomical sites (serous cavities/lymph
and subcutaneous/deep tissue nodules) to mediate Wolbachia depletion. Future clinical studies
will confirm the extent to which our findings are recapitulated in human clinical studies of
ABBV-4083, and potentially with other anti-Wolbachia candidates.
One goal of the current studies was to characterize the kinetics of Wolbachia reduction in
adult female worms after oral ABBV-4083 treatment. In both mice and jirds, the Wolbachia
load declined in a time-dependent manner, beginning as soon as 3 days after treatment start
and continuing through 14 days of treatment in an approximately log-linear fashion. Wolba-
chia levels continued to decline in the weeks following the discontinuation of treatment, a
finding that was also observed for in vitro Wolbachia depletion in insect cells by doxycycline
[33]. The depletion of Wolbachia was associated with profoundly disrupted embryogenesis,
resulting in sterilization of adult female worms and the ablation of microfilariae production
and release. The observed clearance of peripheral microfilaremia by ABBV-4083 was compara-
ble to previous studies in L. sigmodontis-infected jirds using the anti-Wolbachia candidates
ABBV-4083 and AWZ1066S starting at 8wpt and reaching complete absence of peripheral
microfilariae by 12-15wpt [17, 18, 23]. Kinetic analysis of the embryogenesis indicated that as
early as 4wpt the number of stretched microfilariae within the uteri were reduced by>90%,
consistent with a half-life of the microfilariae within the peripheral blood of around 3–4 weeks
[34] and a drop of peripheral microfilariae loads beginning around 8wpt.
In contrast to the complete absence of microfilariae after two weeks of ABBV-4083 treat-
ment, suboptimal treatment for two weeks with BID doxycycline maximally lowered microfi-
lariae levels by 98.6% at week 13, followed by the onset of a rebound by 14wpt, consistent with
the recrudescence of Wolbachia observed in the adult worms from animals in that group. Sim-
ilar results were observed in previous L. sigmodontis jird studies that used the suboptimal two-
week regimen of doxycycline as a treatment time-matched control for ABBV-4083 and
AWZ1066S [18, 23]. Similarly, human clinical studies have shown that at least 4 weeks of doxy-
cycline therapy is required to achieve a macrofilaricidal effect in lymphatic filariasis and
onchocerciasis patients [1, 8, 15, 31, 32]. These data indicate the importance of evaluating
Wolbachia depletion kinetics
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Wolbachia depletion over a period of several months in the jird model, as shorter observation
periods may miss the recrudescence of Wolbachia and the rebound of microfilariae. Through
use of this extended analysis period, our results confirm that two weeks of ABBV-4083 QD
75mg/kg treatment are superior in regard to Wolbachia depletion, microfilariae clearance and
disruption of embryogenesis in comparison to a suboptimal two weeks of doxycycline treat-
ment [18]. Since both ABBV-4083 (a macrolide) and doxycycline (a tetracycline) are expected
to be bacteriostatic on the basis of inhibition of prokaryotic protein synthesis, the differences
in kinetics observed in our studies is likely due to the substantial difference in in vitro potency
between the two agents [18] rather than a consequence of mechanistic distinctions. The results
of the current studies verify that the efficacy of ABBV-4083 is both dose- and treatment dura-
tion-dependent and provide the basis for exploration of 7- to 14-day regimens in clinical
studies.
Importantly, the kinetics of Wolbachia depletion in female adult worms was recapitulated
by the Wolbachia depletion in microfilariae. Thus, already at 1wpt, Wolbachia were reduced in
the majority of microfilariae of doxycycline or ABBV-4083 treated animals and no Wolbachia
were detectable by 5wpt in both groups. This coincided with a Wolbachia depletion of 92.5%
and 99.7% in female adult worms at 1 and 4wpt of ABBV-4083 treated jirds, respectively. Simi-
larly, while microfilariae of ABBV-4083-treated jirds had no detectable Wolbachia through to
the end of the study at 13wpt, microfilariae from suboptimal doxycycline treated animals dis-
played a rebound of the Wolbachia similar to that observed in the adult worms. The measure-
ment of Wolbachia levels in microfilariae may thus be a suitable indicator for the Wolbachia
depletion and recrudescence in adult worms, allowing for similar kinetic studies on the Wolba-
chia in microfilariae during human clinical trials without the need for repeated surgical
removal of the nodules harboring adult worms from onchocerciasis patients. Our laboratories
have previously sampled microfilariae from the circulation of bancroftian filariasis patients at
3–4 months after commencement of 2–4 week doxycycline regimens in order to determine
anti-Wolbachia efficacy. These clinical data indicate that average anti-Wolbachia depletion lev-
els in microfilariae in patient cohorts shortly following drug removal are indicative of long-
term macrofilaricidal activity, with declines of>90% being predictive of eventual significant
curative activity at 18 months [14, 35, 36]. Our present data corroborate that sampling microfi-
lariae in the periphery will likely be an acceptable surrogate indicator of anti-Wolbachia effi-
cacy within adult filarial worms following treatment of the clinical candidate ABBV-4083, and
thus may be predictive of long-term efficacy. A first proof of concept that Wolbachia can be
determined from microfilariae of O. volvulus patients as well was previously demonstrated by
our laboratory [37]. However additional work is needed to allow the measurement from
human skin samples that contain only a single or few microfilariae.
The results of our studies suggest that BID vs. QD dosing of ABBV-4083 produces only a
modest increase in efficacy, equivalent to a small increase in QD dose, despite the short plasma
half-life of ABBV-4083 in mice [18]. Instead, increasing the number of days of QD dosing
appears to have a greater effect on efficacy than BID dosing for a shorter duration. This obser-
vation is consistent with the fact that Wolbachia is a slowly replicating organism (doubling
time 14 h in insect cells [38] and much longer in filarial worms [39], where they cannot con-
tinue to multiply in adult worms without overloading and damaging their host) and the obser-
vations that Wolbachia levels continue to decline after dosing is completed. Thus, these studies
provide support for investigation of a QD rather than BID dosing regimen of ABBV-4083 in
clinical studies of efficacy irrespective of its half-life in humans.
Finally, in the context of a regimen of 7 or 14 daily doses of ABBV-4083, omitting 2 or 4
days of dosing, respectively, did not impair Wolbachia depletion in comparison to consecutive
7 or 14 daily treatments, provided that the missed daily doses were given after the originally
Wolbachia depletion kinetics
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007636 August 5, 2019 15 / 19
planned end of treatment to complete the 7- or 14-day treatments with the regimen. This result
may also be related to the slow replication rate of Wolbachia. This study was designed to
mimic a pattern of incomplete adherence to a 7- or 14-day regimen in humans. The equivalent
anti-Wolbachia efficacy of matched continuous and discontinuous groups in Fig 4B suggests
that clinical efficacy may not be compromised by some missed doses, as long as the missed
doses are given at the end of treatment, consistent with our clinical trials on doxycycline where
we also allowed missed treatments to be completed at the end of treatment [15, 40, 41]. In this
regard, instructing patients to complete the entire regimen with once daily dosing even if days
are missed may be useful.
In conclusion, our results demonstrate that treatment duration rather than BID vs. QD
treatment primarily determines the efficacy of ABBV-4083. Furthermore, they indicate that
some degree of variable, incomplete adherence to the dosing regimen may be acceptable with-
out seriously impairing the Wolbachia depletion efficacy, provided that the regimen is subse-
quently completed. The Wolbachia depletion was shown to occur within days after start of
anti-Wolbachia therapy, and levels continued to decline during the weeks following the end of
treatment. The depletion of Wolbachia is associated with profoundly disrupted embryogenesis,
sterilization of adult female worms, and the ablation of microfilarial production and release.
Finally, the correlation of Wolbachia decline and recrudescence between adult worms and
microfilariae in this model provides a basis for exploration of Wolbachia levels in skin microfi-
lariae as a surrogate indicator for anti-Wolbachia activity in O. volvulus infection.
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